Ultragenyx Pharmaceutical Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 81.65 million compared to USD 81.47 million a year ago. Net loss was USD 73 million compared to USD 68.85 million a year ago. Basic loss per share from continuing operations was USD 1.08 compared to USD 1.13 a year ago. For the nine months, revenue was USD 268.02 million compared to USD 179.49 million a year ago. Net loss was USD 331.57 million compared to USD 162.56 million a year ago. Basic loss per share from continuing operations was USD 4.91 compared to USD 2.73 a year ago.